Article Versions Notes

Gage M, Putra M, Wachter L, Dishman K, Gard M, Gomez-Estrada C, Thippeswamy T. Saracatinib, a Src Tyrosine Kinase Inhibitor, as a Disease Modifier in the Rat DFP Model: Sex Differences, Neurobehavior, Gliosis, Neurodegeneration, and Nitro-Oxidative Stress. Antioxidants. 2022; 11(1):61. https://doi.org/10.3390/antiox11010061

Gage, Meghan, Marson Putra, Logan Wachter, Kylie Dishman, Megan Gard, Crystal Gomez-Estrada, and Thimmasettappa Thippeswamy. 2022. "Saracatinib, a Src Tyrosine Kinase Inhibitor, as a Disease Modifier in the Rat DFP Model: Sex Differences, Neurobehavior, Gliosis, Neurodegeneration, and Nitro-Oxidative Stress" Antioxidants 11, no. 1: 61. https://doi.org/10.3390/antiox11010061

Gage, M., Putra, M., Wachter, L., Dishman, K., Gard, M., Gomez-Estrada, C., & Thippeswamy, T. (2022). Saracatinib, a Src Tyrosine Kinase Inhibitor, as a Disease Modifier in the Rat DFP Model: Sex Differences, Neurobehavior, Gliosis, Neurodegeneration, and Nitro-Oxidative Stress. Antioxidants, 11(1), 61. https://doi.org/10.3390/antiox11010061